References
- Unal M, Peyman GA, Liang C, et al. Ocular toxicity of intravitreal clarithromycin. Retina 1999;19:442–446
- Tayagi AK, Kayarkar VV, McDonnell PJ. An unreported side effect of topical clarithromycin when used successfully to treat mycobacterium avium-intracellulare keratitis. Cornea 1999;18:606–607
- Tugal-Tutkun I, Araz B, Tsakapili M, et al. Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. Am Acad Ophthalmol 2009;116:1552–1557
- Tugal-Tutkun I, Urgancioglu M. Bilateral acute depigmentation of the iris. Graefe’s Arch Clin Exp Ophthalmol 2006;244:742–746
- Bhagat N, Read RW, Rao NA, et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Am Acad Ophthalmol 2001;108:750–752
- Bettink-Remeijer MW, Brouwers K, Van Langenhove L, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye 2009;23:2260–2262
- Siefert HM, Kohlsdorfer C, Steinke W, Witt A. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin:tissue distribution in male rats. J Antimicrob Chemother 1999;43:61–67
- Quinney SA, Zhang X, Lucksiri A, et al. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metabol Dispos 2010;38:241–248
- Traunmuller F, Zeitlinger M, Zeleny P, et al. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob Agents Chemother 2007;51:3185–3189
- Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hospital Infection 1991;19:29–37